Valeant Pharmaceuticals - חוב כולל להון BHC

This daily price chart for Bausch Health Companies (BHC) demonstrates a debt-to-equity ratio of 0.00. The business relies on contract pharmaceutical manufacturing and third-party logistics. Current successes are tied to the protection of Xifaxan rights and the launch of new products. To balance its massive liabilities, the holding company is executing a spin-off, separating its most profitable ophthalmology segment.

Stable demand for Bausch Health Companies (BHC) ophthalmology and over-the-counter drugs creates a defensive business profile, minimizing operational risks. An analysis of the current total liabilities-to-equity ratio allows for an assessment of the proportion of debt within the financing structure relative to equity, where a decrease in this coefficient confirms recovering solvency and improved net income quality through increased free cash flow.